Table 3.
PTLD risk associated with HCV status at the time of transplantation among 210 763 solid organ transplant recipients by PTLD subtype and type of organ transplanted
| Patients with PTLD, no. | HCV+, HR (95% CI)* | HCV status unknown, HR (95% CI)* | |
|---|---|---|---|
| Total | 1630 | 0.84 (0.68-1.05) | 0.84 (0.73-0.98) |
| By PTLD site | |||
| Liver | 208 | 1.06 (0.62-1.82) | 0.93 (0.62-1.40) |
| Nonliver | 1422 | 0.81 (0.64-1.03) | 0.83 (0.71-0.97) |
| Allograft | 266 | 1.11 (0.68-1.79) | 1.09 (0.78-1.54) |
| Nonallograft | 1364 | 0.80 (0.63-1.01) | 0.80 (0.68-0.94) |
| By PTLD pathology† | |||
| Polymorphic | 584 | 0.99 (0.69-1.41) | 0.98 (0.78-1.24) |
| Monomorphic | 825 | 0.86 (0.64-1.15) | 0.83 (0.67-1.02) |
| Other/unknown | 221 | 0.49 (0.24-1.00) | 0.56 (0.35-0.90) |
| By PTLD cell type | |||
| B cell | 1100 | 0.90 (0.70-1.16) | 0.85 (0.71-1.02) |
| T cell | 127 | 0.80 (0.36-1.74) | 1.09 (0.67-1.75) |
| Unknown | 403 | 0.70 (0.44-1.12) | 0.76 (0.56-1.03) |
| By PTLD EBV status | |||
| Negative | 238 | 1.04 (0.63-1.70) | 1.07 (0.75-1.53) |
| Positive | 785 | 0.75 (0.53-1.08) | 0.85 (0.69-1.05) |
| Unknown | 607 | 0.87 (0.63-1.20) | 0.75 (0.58-0.97) |
| By PTLD latency | |||
| Less than 1 y after transplantation | 627 | 0.71 (0.50-1.01) | 0.88 (0.69-1.11) |
| 1 to 4 y after transplantation | 535 | 1.02 (0.75-1.39) | 0.85 (0.67-1.07) |
| Over 5 y after transplantation | 468 | 0.77 (0.45-1.32) | 0.78 (0.58-1.06) |
| By organ type | |||
| Heart and/or lung | 513 | 1.53 (0.79-2.96) | 0.84 (0.63-1.11) |
| Kidney and/or pancreas | 698 | 0.55 (0.30-1.01) | 0.85 (0.67-1.08) |
| Liver | 382 | 0.83 (0.61-1.13) | 0.73 (0.56-0.96) |
| Other | 37 | 1.84 (0.52-6.53) | 0.65 (0.30-1.37) |
*
Adjusted for age, sex, race/ethnicity, and education. HCV− recipients were used as the referent group in all analyses.
†
PTLD pathology refers to morphologic classification of tumor cell size and shape as heterogeneous (″polymorphic PTLD″) or homogeneous (″monomorphic PTLD″). Both disease entities are thought to be monoclonal.